Danuglipron - Pfizer
Alternative Names: Danuglipron tromethamine; PF-06882961; PF-06882961 tromethamine; PF-06882961-82Latest Information Update: 09 Oct 2024
At a glance
- Originator Pfizer
- Class Antihyperglycaemics; Benzimidazoles; Carboxylic acids; Fluorinated hydrocarbons; Obesity therapies; Piperidines; Pyridines; Small molecules
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Obesity; Type 2 diabetes mellitus
- Discontinued Non-alcoholic steatohepatitis
Most Recent Events
- 28 Aug 2024 Pfizer initiates a phase-I pharmacokinetics trial for Obesity (In volunteers) in USA (PO, Tablet) (NCT06567327),
- 28 Aug 2024 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in China (PO, Tablet)
- 27 Aug 2024 Pfizer plans to initiate a phase I trial for Obesity (PO) (NCT06567327)